Pernix Therapeutics Holdings, Inc., a specialty pharmaceutical company, engages in the development, marketing, and sale of branded and generic pharmaceutical products primarily for the pediatric market. Its promoted product families include ALDEX Line, a line of antihistamines, decongestants, and cough suppressants indicated for the temporary relief of respiratory allergies, allergic rhinitis, and symptoms of the common cold; BROVEX Line, a line of antihistamine combinations with the API brompheniramine maleate indicated for the temporary relief of sneezing, itchy, watery eyes, itchy nose or throat, and runny nose due to hay fever or other respiratory allergies; CEDAX Line, a third generation oral cephalosporin indicated for the treatment of mild to moderate acute bacterial exacerbations of chronic bronchitis, and middle ear infection due to haemophilus influenza or streptococcus pyogenes; Natroba Topical Suspension, a prescription medicine used to treat head lice in adults and children of four years of age and older; PEDIATEX Line, which includes PEDIATEX TD, an antihistamine/nasal decongestant combination liquid for oral administration; and ZEMA-PAK, an oral corticosteroid tablet used for the treatment of dermatological diseases, including poison ivy, allergic states, and contact dermatitis. The company also sells various other products for pediatric indications, including REZYST IM, a proprietary probiotic blend that promotes microflora growth and colonization; and generic versions of selected branded products. In addition, it engages in the development of Theobromine, a non-codeine and non-opiod treatment for cough. The company